Recent researches show that common immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 are only effective in patients with advanced/recurrent ovarian cancer, but the clinical efficacy is very limited. The gene discussed is CTLA4; the disease is ovarian cancer.